Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
9.30
-0.58 (-5.87%)
Nov 16, 2026, 9:51 AM EST - Market open
Biodesix Revenue
Biodesix had revenue of $24.04M in the quarter ending September 30, 2026, with 10.44% growth. This brings the company's total for the last twelve months to $105.21M, up 31.23% year-over-year. In the year 2025, Biodesix had annual revenue of $88.50M with 24.08% growth. That makes Biodesix the 22,310th largest company in the world by revenue and 3,259th in the United States.
Revenue (ttm)
$105.21M
Revenue Growth
+31.23%
P/S Ratio
1.04
Revenue / Employee
$315,006
Employees
334
Market Cap
103.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 88.50M | 17.18M | 24.08% |
| Dec 31, 2024 | 71.32M | 22.24M | 45.30% |
| Dec 31, 2023 | 49.09M | 10.88M | 28.46% |
| Dec 31, 2022 | 38.21M | -16.29M | -29.89% |
| Dec 31, 2021 | 54.51M | 8.95M | 19.64% |
| Dec 31, 2020 | 45.56M | 21.01M | 85.55% |
| Dec 31, 2019 | 24.55M | 4.12M | 20.16% |
| Dec 31, 2018 | 20.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 803.60M |
| OPKO Health | 654.10M |
| Castle Biosciences | 377.13M |
| Fulgent Genetics | 330.28M |
| Freenome | 217.86M |
| MDxHealth | 114.01M |
| Burning Rock Biotech | 73.70M |
| Exagen | 72.30M |
BDSX News
- 5 days ago - Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors - GlobeNewsWire
- 5 days ago - Biodesix Transcript: UBS Global Healthcare Conference - Transcripts
- 7 days ago - Biodesix price target lowered to $34 from $38 at H.C. Wainwright - TheFly
- 7 days ago - Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting - GlobeNewsWire
- 10 days ago - Biodesix price target lowered to $30 from $40 at Lake Street - TheFly
- 10 days ago - Biodesix price target lowered to $34 from $40 at TD Cowen - TheFly
- 10 days ago - Biodesix sees FY26 revenue $101M-$103M, consensus $111.82M - TheFly
- 10 days ago - Biodesix reports Q3 EPS (75c) vs. ($1.16) last year - TheFly